ABOS
Acumen Pharmaceuticals, Inc.
Industry
Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Loading...
Open
2.09
Mkt cap
122M
Volume
337K
High
2.09
P/E Ratio
-1.47
52-wk high
5.09
Low
1.95
Div yield
N/A
52-wk low
1.95

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.